Publications by authors named "M Kramski"
Article Synopsis
- NK cells from HIV-infected individuals show unique changes, including increased activation markers and a decreased presence of the signal protein FcRγ, which persists even in those under effective antiretroviral treatment (cART).
- A new subtype of NK cells has been identified that lacks FcRγ and has distinct activation properties, making up a significant portion of CD56(dim) NK cells in both untreated and treated HIV-infected individuals.
- These FcRγ(-) NK cells exhibit stronger antibody-dependent cytotoxicity against certain targets, and their abundance is related to other immune responses and inflammatory markers, which could affect how well the immune system functions in HIV patients on cART.
There is growing interest in the role of anti-HIV antibody-dependent cellular cytotoxicity (ADCC) antibodies in the prevention and control of HIV infection. Passive transfer studies in macaques support a role for the Fc region of antibodies in assisting in the prevention of simian-human immunodeficiency virus (SHIV) infection. The Thai RV144 HIV-1 vaccine trial induced anti-HIV ADCC antibodies that may have played a role in the partial protection observed.
View Article and Find Full Text PDFBackground: Combination antiretroviral therapy (cART) effectively controls human immunodeficiency virus (HIV) infection but does not eliminate HIV, and lifelong treatment is therefore required. HIV-specific cytotoxic T lymphocyte (CTL) responses decline following cART initiation. Alterations in other HIV-specific immune responses that may assist in eliminating latent HIV infection, specifically antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent phagocytosis (ADP), are unclear.
View Article and Find Full Text PDFObjective: The objective of this study is to determine the breadth of HIV-1 Env-specific antibody-dependent cellular cytotoxicity (ADCC) in HIV controllers and HIV progressors with a view to design globally relevant HIV vaccines.
Design: The breadth of ADCC towards four major HIV-1 Env subtypes was measured in vitro for 11 HIV controllers and 11 HIV progressors.
Methods: Plasma from 11 HIV controllers (including long-term slow progressors, viremic controllers, elite controller and posttreatment controller) and 11 HIV progressors, mostly infected with HIV-1 subtype B, was analysed for ADCC responses.
Article Synopsis
- Intravenous immunoglobulin (IVIG) is a treatment derived from human antibodies that helps in managing immune deficiencies, infections, and autoimmune diseases.
- Research tested various IVIG preparations from before and after the 2009 H1N1 influenza pandemic for their ability to produce immune responses specific to influenza.
- Results showed that some IVIG preparations contained antibodies that could effectively target and recognize multiple strains of influenza, suggesting IVIG could offer protective benefits during pandemic situations, especially for high-risk individuals.